GlassScriptPhysician profile
Anna Marlene Gaidis
NPI 1083107528
$489.11
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $104 · 2022: $56.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $126.97 | 2019 | |
| Amniox Medical, INC. | $107.20 | 2019 | |
| Abbvie INC. | $103.84 | 2020 | |
| Boston Scientific Corporation | $60.78 | 2019 | |
| Baxter Healthcare | $56.26 | 2022 | |
| Incyte Corporation | $19.32 | 2019 | |
| Dova Pharmaceuticals | $14.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Gaidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.